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Nardilysin (NRDC) is a metalloendopeptidase of the M16 family. We previously
showed that NRDC activates inflammatory cytokine signaling, including inter-
leukin-6-signal transducer and activator of transcription 3 (STAT3) signaling.
NRDC has been implicated in the promotion of breast, gastric and esophageal
cancer, as well as the development of liver fibrosis. In this study, we investigated
the role of NRDC in the promotion of hepatocellular carcinoma (HCC), both clini-
cally and experimentally. We found that NRDC expression was upregulated three-
fold in HCC tissue compared to the adjacent non-tumor liver tissue, which was
confirmed by immunohistochemistry and western blotting. We also found that
high serum NRDC was associated with large tumor size (>3 cm, P = 0.016) and
poor prognosis after hepatectomy (median survival time 32.0 vs 73.9 months,
P = 0.003) in patients with hepatitis C (n = 120). Diethylnitrosamine-induced hep-
atocarcinogenesis was suppressed in heterozygous NRDC-deficient mice com-
pared to their wild-type littermates. Gene silencing of NRDC with miRNA
diminished the growth of Huh-7 and Hep3B spheroids in vitro. Notably, phospho-
rylation of STAT3 was decreased in NRDC-depleted Huh-7 spheroids compared to
control spheroids. The effect of a STAT3 inhibitor (S3I-201) on the growth of
Huh-7 spheroids was reduced in NRDC-depleted cells relative to controls. Our
results show that NRDC is a promising prognostic marker for HCC in patients
with hepatitis C, and that NRDC promotes tumor growth through activation of
STAT3.
H epatocellular carcinoma (HCC) is one of the most com-mon cancers and the third leading cause of cancer-related
deaths worldwide.(1) Low-grade inflammation, induced by
chronic hepatitis B and C and steatohepatitis, is the established
pathogen of HCC,(2) but much remains to be learned about
how HCC initiates and progresses. The long-term prognosis of
HCC, even after curative surgical resection or percutaneous
ablation therapy, is unsatisfactory because of the high inci-
dence of recurrence, with a 3-year and 5-year recurrence rate
of more than 50 and 70%, respectively.(3–5) Although sorafe-
nib, a multi-kinase inhibitor, has been established as the stan-
dard therapy for advanced HCC,(5) even with such treatment,
the prognosis for advanced HCC remains dismal, with a med-
ian survival time of less than 1 year.(6) Identification of novel
therapeutic targets for HCC is urgently needed.
Nardilysin (N-arginine dibasic convertase = NRDC) is a
metalloendopeptidase of the M16 family. We first identified
NRDC as a specific binding protein of the heparin-binding
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Fig. 1. Nardilysin (NRDC) is upregulated in hepatocellular carcinoma (HCC) tissue and serum NRDC is a prognostic marker for HCC patients with
hepatitis C. (a) Immunohistochemistry for an anti-human NRDC mouse monoclonal antibody (#102). Scale bar represents 500 lm. (b,c) Western
blotting for an anti-human NRDC mouse monoclonal antibody (#23) for tumor (T) and the adjacent non-tumor liver tissue (NT). The expression
level of NRDC is quantified by densitometry and normalized to b-actin. The expression levels of NT and T are converted to logarithms, which are
compared using the paired t-test for each patient (n = 27). (d) Comparison of serum NRDC in healthy volunteers (n = 112) and HCC patients
(n = 220). Data are expressed as a scatter plot and a box-and-whisker plot. The box, horizontal bar in the box, and whisker represent the
interquartile range, median, and quartile to the outermost value within a 1.5 9 interquartile range, respectively. Wilcoxon’s test is used for sta-
tistical comparison. (e) Scatter plot of histological NRDC expression (tumor to non-tumor ratio) and serum NRDC in each patient (n = 27). Linear
correlation is examined using Pearson’s correlation analysis. (f–h) Kaplan–Meier curves of overall survival (f), recurrence-free survival (g) and sur-
vival after recurrence (h) related to the serum NRDC in patients with hepatitis C. The cutoff value is determined as 844.6 pg/mL by receiver oper-
ating characteristic analysis for the outcome of death within 3 years of surgery among patients with hepatitis C. Cumulative survival rates are
compared using the log-rank test.
Cancer Sci | May 2017 | vol. 108 | no. 5 | 911 © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Kasai et al.
epidermal growth factor-like growth factor (HB-EGF).(7)
Thereafter, we showed that NRDC enhances ectodomain shed-
ding of HB-EGF and other membrane proteins, including
tumor necrosis factor-alpha (TNF-a).(8–10) In addition to its
functions at the cell surface, nuclear functions of NRDC as a
transcriptional co-regulator have been identified.(11–13) NRDC
has been implicated in the promotion of breast,(14) gastric(10)
and esophageal cancer.(15) In gastric cancer, we demonstrated
that NRDC promotes cancer cell proliferation through activa-
tion of an interleukin-6-signal transducer and activator of tran-
scription 3 (STAT3) pathway that was induced by the
enhancement of TNF-a shedding. We reported that NRDC also
promotes liver fibrosis in mice via TNF-a signaling.(16)
In the present study, we investigated the role of NRDC in
the promotion of HCC, both clinically and experimentally, and
explored whether NRDC might be a prognostic marker and
therapeutic target for HCC.
Materials and Methods
Patients and clinical samples. For measurement of serum
NRDC, preoperative serum samples were obtained from 220 of
685 patients who underwent hepatectomy for HCC between 1996
and 2006 at the Department of Surgery, Kyoto University Hospi-
tal. As a control group, serum samples were obtained from 112
healthy volunteers who had been shown not to have any
Fig. 2. Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in nardilysin (NRDC)-deficient mice. (a) Hepatocarcinogenesis is assessed
by the tumor number (left lower graph) and maximum tumor size (right lower graph) for wild-type mice (Nrdc +/+, n = 15) and heterozygous
NRDC-deficient mice (Nrdc +/, n = 14). Data are expressed as the mean plus/minus the standard error, which are compared using the unpaired
t-test. Arrowheads indicate tumors. Scale bar represents 10 mm. (b) Immunohistochemistry for an anti-mouse NRDC rat monoclonal antibody
(#135) in the mouse liver. Scale bar represents 100 lm. (c) Immunohistochemistry for Ki67 in the mouse liver. The number of total and Ki67-posi-
tive cells is counted for five random high-power fields per mouse. Data are expressed as the mean plus/minus the standard error of the propor-
tion of Ki67-positive cells of five mice per each genotype, which are compared using the unpaired t-test. Scale bar represents 200 lm for large
panels and 50 lm for small panels.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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malignant disorder. Serum NRDC was measured using an ELISA,
as previously described.(10) Kaplan–Meier analysis was used to
assess the prognostic impact of serum NRDC on overall survival,
recurrence-free survival, and survival after recurrence. Resected
specimens were either preserved as separate fresh-frozen blocks
of the tumor and adjacent non-tumor liver tissue, or fixed in 10%
formalin (Wako, Osaka, Japan) and embedded in paraffin for
immunohistochemistry. Written informed consent was obtained
from all patients. This study was performed in accordance with
the Declaration of Helsinki and the Japanese Ethical Guidelines
for Epidemiological Research, and was approved by the Kyoto
University Graduate School and Faculty of Medicine Ethics Com-
mittee (Approval code: E1840 and R0571).
Cohort study from The Cancer Genome Atlas database. Hepa-
tocellular carcinoma data from The Cancer Genome Atlas
(TCGA) was downloaded from the Broad Institute’s Firehose
pipeline using the RTCGAToolbox.(17) We integrated clinical
data and upper quartile normalized RNAseqv2 data from cancer
tissue. The breakpoint of log2-transformed upper quartile frag-
ments per kilobase of exon per million reads mapped (FPKM-
UQ) of the NRDC gene was determined using the classification
and regression tree (CART) technique.(18) For analysis of the
TCGA database, R and the Bioconductor survival,(19) party,(18)
MASS,(20) stringr(21) and RTCGAToolbox packages were used.
Mice and the hepatocarcinogenesis model. Heterozygous
NRDC-deficient mice (Nrdc +/) (Accession No. CDB0466K,
http://www.clst.riken.jp/arg/mutant%20mice%20list.html) on a
C57BL/6 background were used along with wild-type litter-
mates.(22) Mice were maintained in filter-topped cages and fed
an autoclaved diet of regular chow and tap water according to
the guidelines of the Institutional Animal Care and Use Com-
mittee of Kyoto University. In the diethylnitrosamine (DEN,
Sigma-Aldrich, St. Louis, MO, USA)-induced hepatocarcino-
genesis model, DEN (25 mg/kg) was injected intraperitoneally
into mice once on day 14 after birth.(23) Mice were killed at
36 weeks of age and liver tissue was collected and rapidly
fixed in 10% formalin for immunochemical analysis.
Cell lines, reagents, and stable knockdown of nardilysin and
STAT3. Human HCC cell lines, Huh-7 and Hep3B, were cul-
tured in DMEM (Thermo Fisher, Scientific, Waltham, MA,
USA) supplemented with 10% FBS and 1% penicillin/strepto-
mycin under 5% CO2 at 95% humidity and 37°C. Gene knock-
down of NRDC or STAT3 in Huh-7 and Hep3B cells was
performed by transduction of lentiviral vectors expressing




2, 50-TTGTGGTGATCTCCAACATCT-30. We used a control
vector that contained a non-targeting sequence for any verte-
brate gene as a negative control (NC).
Multicellular spheroid growth assay. Huh-7 and Hep3B cells
were seeded into 96-well round bottom ultra-low attachment
microplates (Corning, NY, USA) at densities of 1000 and 2500
cells, respectively, in 200 lL of growth medium supplemented
with 10% FBS per well. The cells were allowed to sponta-
neously aggregate, as described previously.(24) Spheroids were
observed with an inverted microscope (Keyence, Osaka, Japan)
and the sectional area [S (910 000 lm2)] of each spheroid was
measured with Image J software (NIH, Bethesda, MD, USA).
The volume index of the spheroid was calculated as S1.5.
Spheroid growth inhibition assay. S3I-201 (a small molecule
STAT3 inhibitor, Santa Cruz Biotechnology, Dallas, TX,
USA), dissolved in DMSO (Wako), was added to growth
medium supplemented with 10% FBS immediately after cell
seeding into 96-well ultra-low attachment microplates. Equiva-
lent amounts of DMSO were used as the control for S3I-201.
The effect of S3I-201 on spheroid growth was evaluated after
7 days of treatment.
Immunohistochemistry. Immunohistochemistry was performed
as previously described.(10) Four-lm thick sections were incu-
bated with the indicated primary antibody (4°C overnight): anti-
human NRDC mouse monoclonal antibody (#102, established
in our laboratory) for human liver specimens, dilution 1:500;
anti-mouse NRDC rat monoclonal antibody (#135, established
in our laboratory) for mouse liver specimens, dilution 1:200;
and Ki67 (DakoCytomation, Glostrup, Denmark) for mouse
liver specimens, dilution 1:100. Human specimens were incu-
bated with Mouse EnVision Polymer (DAKO) at room tempera-
ture for 1 h. Mouse specimens were incubated with biotinylated
secondary antibody for 1–2 h and then with the avidin–biotin–
peroxidase complex (Vectastain ABC Kit, Vector Laboratories,
Burlingame, CA, USA) at room temperature for 30 min.
Western blotting. Western blotting was performed as previ-
ously described.(13) Twenty lg of tissue lysate, or 10 lg of
cell lysate isolated from spheroids, was electrophoresed on a
10% SDS-polyacrylamide gel (SDS from Wako; acrylamide
from Bio Rad, Hercules, CA, USA) and transferred to a nitro-
cellulose membrane (GE Healthcare, Buckinghamshire, UK).
The targets of the primary antibodies are listed in Table S1.
The blot was observed with EZ-Capture II software (ATTO,
Tokyo, Japan) after being visualized by ECL Prime (GE







Age ≥/<65 33/22 41/24 0.730
Sex M/F 43/12 53/12 0.647
HBs-antigen (+) 3 (5.5%) 1 (1.5%) 0.228
Child-Pugh A/B 50/5 60/5 0.783




Single/multiple tumor 34/21 33/32 0.224
Tumor size >3 cm 29 (52.7%) 48 (73.9%) 0.016
Vascular invasion (+) 25 (45.5%) 36 (55.4%) 0.278
Extrahepatic metastasis (+) 0 (0%) 4 (6.2%) 0.025
Poor differentiation 13 (23.6%) 17 (27.0%) 0.677
The cutoff value is 844.6 pg/mL. Liver cirrhosis is confirmed by patho-
logical examination of the resected specimens. Differentiation was
unknown in 2 patients because of tumor necrosis. HBs-antigen: hep-
atitis B surface antigen.
Table 2. Cox proportional hazard model for overall survival for
patients with hepatitis C
HR 95% CI P-value
Multiple tumor 1.56 1.00–2.43 0.049
Vascular invasion (+) 1.94 1.25–3.04 0.003
Liver cirrhosis 2.05 1.31–3.22 0.002
Serum NRDC ≥844.6 pg/mL 1.92 1.23–3.03 0.004
Patients with 30-day mortality or extrahepatic metastasis are excluded
from this analysis. Because large tumor size (>3 cm) is correlated with
high serum NRDC, tumor size is not included in this multivariate anal-
ysis as an independent variable. CI, confidence interval; HR, hazard
ratio; NRDC, nardilysin.
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Healthcare). Analysis of densitometry was performed using
Image J software.
Statistical analysis. Continuous variables were expressed as
the median or the mean plus/minus the standard error, and
compared using Wilcoxon’s test, or the paired or unpaired
t-test, as appropriate. Categorical variables were compared
using the v2-test. The optimal cutoff value of serum NRDC
that defined the prognosis of HCC was determined according
to receiver operating characteristic analysis for the outcome of
death within 3 years of surgery. Cumulative survival rates
were calculated using the Kaplan–Meier method and compared
using the log-rank test. Multivariate analysis for overall sur-
vival was performed using the Cox proportional hazard model.
A two-tailed P-value < 0.05 was considered to be significant.
Statistical analyses were performed using JMP software ver-
sion 10 (SAS Institute, Cary, NC, USA).
Results
Nardilysin is upregulated in hepatocellular carcinoma tissue
and serum nardilysin is a prognostic marker for hepatocellular
carcinoma patients with hepatitis C. Immunohistochemistry
using an anti-NRDC antibody revealed that NRDC expression
was higher in HCC compared to the adjacent non-tumor liver tis-
sue (Fig. 1a). This finding was confirmed by western blot analy-
sis, which showed that NRDC expression was upregulated
threefold in HCC compared to the adjacent non-tumor liver tis-
sue (Fig. 2b,c). Serum NRDC was 1.7 times higher in HCC
patients compared to healthy volunteers (median 934.1 vs
539.8 pg/mL, respectively, P < 0.001, Fig. 1d), and correlated
modestly, but positively, with the tumor to non-tumor ratio of
histological NRDC expression (Fig. 1e). These results suggest
that the systemic concentration of NRDC reflects the amount of
NRDC in cancer tissues. Serum NRDC did not correlate with
tumor multiplicity, vascular invasion or background liver cirrho-
sis, but did correlate with tumor size and extrahepatic metastasis
(Tables 1 and S2). Overall survival for all patients was not asso-
ciated with serum NRDC (Fig. S1a). However, among patients
with hepatitis C (n = 120), overall survival was significantly
shorter in patients with high serum NRDC than in those with
low serum NRDC (median survival time 32.0 vs 73.9 months,
respectively, P = 0.003, Fig. 1f). Interestingly, survival after
Fig. 3. Gene knockdown of nardilysin (NRDC)
suppresses spheroid growth and STAT3
phosphorylation in hepatocellular carcinoma (HCC)
cells. (a,b) Multicellular spheroid growth assay in
96-well ultra-low attachment plates for HCC cell
lines, Huh-7 (a) and Hep3B (b). Seeding densities
are 1000 cells and 2500 cells for Huh-7 and Hep3B
cells, respectively. Volume index represents the S1.5
[S = sectional area of the spheroid (910 000 lm2)].
Representative data from three independent
experiments are shown. Data are expressed as the
mean plus/minus the standard error of six wells,
which are compared using the unpaired t-test
(*P < 0.05, **P < 0.01, ***P < 0.001). Scale bar
represents 100 lm. (c) Western blotting of
spheroid-derived protein from Huh-7 cells.
Expression levels of phosphorylated proteins and b
actin are quantified by densitometry, and the mean
expression ratio and 95% confidence interval of
knockdown cells to control cells of five
independent experiments are described. Asterisks
(*) represent that the 95% confidence interval does
not cross 1.0.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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recurrence, rather than recurrence-free survival, differed signifi-
cantly between patients with high serum NRDC levels and those
with low serum NRDC (median survival time 27.8 vs
49.0 months, respectively; P = 0.023, Figs 1g,h and S1b,c). In
multivariate analysis among patients with hepatitis C, high
serum NRDC was an independent prognostic factor for overall
survival (Table 2). Thus, high expression of NRDC in cancer
tissues correlates with poor prognosis for HCC patients with
hepatitis C. Consistent with our observations, survival analysis
using the TCGA database showed that high NRDC gene expres-
sion in HCC was associated with poor prognosis (Fig. S2a,b).
These findings strongly suggest that NRDC is a prognostic mar-
ker for HCC in patients with hepatitis C.
Diethylnitrosamine-induced hepatocarcinogenesis is suppressed
in nardilysin-deficient mice. To determine the involvement of
NRDC in the pathogenesis of HCC, DEN-induced hepatocar-
cinogenesis, a well-established mouse model of HCC, was
examined in NRDC-deficient mice. As homozygous deficient
mice show multiple phenotypes, including growth retardation
and hypothermia,(12,22) we used heterozygous deficient (Nrdc
+/) mice for our experiments. Hepatocarcinogenesis was sup-
pressed in Nrdc +/ mice compared to Nrdc +/+ mice, as
assessed by macroscopic tumor number and maximum tumor
size (Fig. 2a). As in human HCC, NRDC was upregulated in
the liver tumor compared to the adjacent non-tumor tissue,
even in Nrdc +/ mice (Fig. 2b). The proportion of Ki67-posi-
tive proliferating cells was significantly lower in the livers of
Nrdc +/ mice compared to the livers of Nrdc +/+ mice
(Fig. 2c). These results indicate that NRDC expression corre-
lates positively with tumor cell proliferation.
Gene knockdown of nardilysin suppresses spheroid growth
and STAT3 phosphorylation in hepatocellular carcinoma cells. To
explore the function of NRDC in HCC cells, NRDC was stably
knocked down using miRNA in Huh-7 and Hep3B cells from
which spheroids were developed, as described in the Methods.
Three-dimensional multicellular spheroid growth assays then
demonstrated that gene silencing of NRDC suppressed Huh-7
and Hep3B spheroid growth (Fig. 3a,b). Of note, phosphoryla-
tion of STAT3 at tyrosine 705 was significantly decreased in
spheroids of NRDC-knockdown Huh-7 cells (Fig. 3c). STAT3
is one of the key promoters of HCC,(25) and we previously
showed that NRDC induces STAT3 phosphorylation in gastric
cancer cells.(10) To confirm the role of STAT3 in spheroid
growth, we established Huh-7 cells stably transduced with a
lentiviral vector expressing miRNA against STAT3. Knock-
down of STAT3 decreased STAT3 phosphorylation (Fig. 4a)
and suppressed spheroid growth (Fig. 4b). Furthermore, a
small molecule STAT3 inhibitor (S3I-201) was less effective
in affecting spheroid growth in NRDC knockdown than control
cells (Fig. 4c), which indicates that NRDC regulates spheroid
growth via STAT3 activation.
Discussion
In this study, we investigated whether NRDC contributes to
the promotion of HCC, both clinically and experimentally, and
explored the potential of NRDC as a prognostic marker and
therapeutic target for HCC. Our results show that: (i) NRDC is
upregulated in HCC tissue; (ii) high serum NRDC is associated
with increased tumor size and poor prognosis among patients
with hepatitis C; (iii) DEN-induced hepatocarcinogenesis is
suppressed in NRDC-deficient mice; and (iv) NRDC promotes
the growth of HCC spheroids through activation of STAT3.
Our results suggest that NRDC could be a useful prognostic
marker for HCC in patients with hepatitis C because of its
ability to predict survival time after recurrence; this capacity
of NRDC is unlike that of other markers which predict overall
survival or recurrence after curative treatment for HCC.(26–28)
Survival time after recurrence depends on the pattern of recur-
rence, including the tumor number and size for intrahepatic
recurrence and the presence or absence of extrahepatic spread.
It also depends on the efficacy of the curative treatment for
Fig. 4. Effect of STAT3 inhibition on spheroid
growth. (a) Western blotting of spheroid-derived
protein from Huh-7 cells. (b) Spheroid growth assay
for Huh-7 cells. Seeding density is 1000 cells.
Representative data from three independent
experiments are shown. Data are expressed as the
mean plus/minus the standard error of six wells,
which are compared using the unpaired t-test
(*P < 0.05, **P < 0.01, ***P < 0.001). Scale bar
represents 100 lm. (c) Spheroid growth inhibition
with S3I-201. One-thousand Huh-7 cells were
incubated with 36 lM of S3I-201 (STAT3 inhibitor)
or equivalent amounts of DMSO for 7 days in 96-
well ultra-low attachment plates. Data are
expressed as the mean plus/minus the standard
error of five independent experiments, which are
compared using the unpaired t-test (**P < 0.01; NS,
not significant). Scale bar represents 100 lm.
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recurrent lesions.(29–31) Although serum NRDC at the time of
surgery was not associated with the time to recurrence, we
suggest that this value could be associated with the aggressive
tumor properties that persist after recurrence. This finding
could alter postoperative surveillance; more intensive surveil-
lance could be scheduled in the patients with high serum
NRDC at the time of surgery for the early detection and treat-
ment of recurrent lesions.
We showed that deletion or gene silencing of NRDC dimin-
ished tumor size in a mouse model of HCC in vivo and spher-
oid growth in vitro. The association between serum NRDC
and tumor size in the clinical data is consistent with these
results. We used a 3-dimensional spheroid growth assay to
evaluate in vitro cell growth, because 3-dimensional cell
culture mimics the in vivo tumor characteristics better than
2-dimensional cell culture in terms of cell–cell interactions,
oxygen and chemical gradients, and gene expression pro-
files.(24) In the analysis of signal transduction in HCC cells
derived from spheroids, gene silencing of NRDC decreased
phosphorylation of STAT3. STAT3 is one of the key promot-
ers of HCC and regulates the transcription of genes involved
in cell proliferation, epithelial-to-mesenchymal transition,
angiogenesis, and metastasis.(25,32–34) STAT3 is also associated
with “stemness” and spheroid formation.(35,36) In this study,
we also show that inhibition of STAT3 suppressed spheroid
growth and that NRDC-knockdown cells were less dependent
on STAT3 signaling for spheroid growth. These data indicate
that spheroid growth promoted by NRDC is, at least partially,
mediated by activation of STAT3. This result is compatible
with our previous findings on gastric cancer, showing that
NRDC activates STAT3.(10)
NRDC has many functions, which are dependent on its
cellular localization, including activation of ectodomain shed-
ding on the cell surface,(8–10,22,37) and protease activity in the
cytoplasm.(38) In addition, the nuclear functions of NRDC as a
transcriptional co-regulator have been described.(11–13) Our
preliminary results of chromatin immunoprecipitation sequence
analysis suggest that NRDC and STAT3 co-localize on the
genome of mouse liver tissue. This finding suggests that
NRDC may interact with STAT3 and regulate the activity of
STAT3.
Our clinical data suggest that NRDC promotes HCC in a
hepatitis C virus (HCV)-specific manner. Accumulated evi-
dence suggests a relationship between HCV infection and acti-
vation of STAT3. Replication of HCV generates oxidative
stress in host cells, resulting in the constitutive activation of
STAT3.(39–41) Direct interaction of the HCV core protein and
STAT3 leads to cellular transformation.(42,43) Moreover, the
HCV core protein facilitates the epithelial-to-mesenchymal
transition of HCC cells through STAT3 activation.(34) These
findings indicate that HCV is involved in both the initiation
and promotion of HCC in a STAT3-dependent manner.
Together, NRDC and HCV affect HCC through activation of
STAT3. Given the positive correlation of serum NRDC and
poor prognosis in HCC patients with hepatitis C, NRDC, in
association with HCV, might promote the aggressiveness of
HCC via STAT3 activation, although further study would be
required to confirm this speculation.
In conclusion, NRDC is a novel and unique prognostic mar-
ker that predicts survival after recurrence as well as overall
survival for HCC in patients with hepatitis C. In addition,
NRDC promotes tumor growth, at least in part, through activa-
tion of STAT3, suggesting that NRDC could be a therapeutic
target for HCC.
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